SNPMiner Trials (Home Page)
Report for Clinical Trial NCT03615105
 Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene 
      This study is being done to learn whether a new method to prevent rejection between the donor
      immune system and the patient's body is effective.
    
Name: Hyperfractionated total body irradiation
Description: Hyperfractionated TBI is administered by a linear accelerator at a dose rate of <20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).
 Type: Radiation
Group Labels:  3  Radiation, Thiotepa   Radiation, Thiotepa &  Radiation, Thiotepa & Cyclophosphamide  
 Name: Thiotepa
Description: Thiotepa 5 mg/kg IV
 Type: Drug
Group Labels:  6  Clofarabine, Thiotepa   Clofarabine, Thiotepa &  Clofarabine, Thiotepa & Melphalan  Radiation, Thiotepa   Radiation, Thiotepa &  Radiation, Thiotepa & Cyclophosphamide  
 Name: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg IV
 Type: Drug
Group Labels:  3  Radiation, Thiotepa   Radiation, Thiotepa &  Radiation, Thiotepa & Cyclophosphamide  
 Name: Busulfan
Description: Busulfan (adult/ped dose)
 Type: Drug
Group Labels:  3  Busulfan, Fludarabine   Busulfan, Fludarabine &  Busulfan, Fludarabine & Melphalan  
 Name: Fludarabine
Description: Fludarabine 25 mg/m2 IV
 Type: Drug
Group Labels:  3  Busulfan, Fludarabine   Busulfan, Fludarabine &  Busulfan, Fludarabine & Melphalan  
 Name: Melphalan
Description: Melphalan 70 mg/m2 IV
 Type: Drug
Group Labels:  6  Busulfan, Fludarabine   Busulfan, Fludarabine &  Busulfan, Fludarabine & Melphalan  Clofarabine, Thiotepa   Clofarabine, Thiotepa &  Clofarabine, Thiotepa & Melphalan  
 Name: Clofarabine
Description: Clofarabine 20-30 mg/m2 IV
 Type: Drug
Group Labels:  3  Clofarabine, Thiotepa   Clofarabine, Thiotepa &  Clofarabine, Thiotepa & Melphalan  
 Name: HPC(A) stem cell allograft
Description: All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.
 Type: Procedure
Group Labels:  9  Busulfan, Fludarabine   Busulfan, Fludarabine &  Busulfan, Fludarabine & Melphalan  Clofarabine, Thiotepa   Clofarabine, Thiotepa &  Clofarabine, Thiotepa & Melphalan  Radiation, Thiotepa   Radiation, Thiotepa &  Radiation, Thiotepa & Cyclophosphamide  
 Name: Rituximab
Description: Rituximab 200 mg IV flat dose
 Type: Drug
Group Labels:  9  Busulfan, Fludarabine   Busulfan, Fludarabine &  Busulfan, Fludarabine & Melphalan  Clofarabine, Thiotepa   Clofarabine, Thiotepa &  Clofarabine, Thiotepa & Melphalan  Radiation, Thiotepa   Radiation, Thiotepa &  Radiation, Thiotepa & Cyclophosphamide  
 Name: Rabbit antithymocyte globulin
Description: Rabbit antithymocyte globulin dosing per nomogram. This dynamic nomogram is based on absolute lymphocyte count at the start of conditioning and can result in either 2 or 3 day ATG administration. If a patient requires 2 day administration the subjequent chemotherapies may be moved forward by one day at the treating physician's discretion.
 Type: Device
Group Labels:  9  Busulfan, Fludarabine   Busulfan, Fludarabine &  Busulfan, Fludarabine & Melphalan  Clofarabine, Thiotepa   Clofarabine, Thiotepa &  Clofarabine, Thiotepa & Melphalan  Radiation, Thiotepa   Radiation, Thiotepa &  Radiation, Thiotepa & Cyclophosphamide  
  Primary Outcomes 
 Description: The intervention will be considered unpromising if the rate of GVHD is greater than 40% and promising if the rate is 20% or less.
 Measure: the number of incidences of grade 3-4 acute GVHD
 Time: 2 years
   
Purpose: Treatment
Allocation: Non-Randomized
Parallel Assignment 
There is one SNP
SNPs
1 T351I 
T351I mutation). --- T351I ---